The maturation of RAS GTPases and approximately 200 other cellular CAAX proteins involves three enzymatic steps: addition of a farnesyl or geranylgeranyl prenyl lipid to the cysteine (C) in the C-terminal CAAX motif, proteolytic cleavage of the AAX residues and methylation of the exposed prenylcysteine residue at its terminal carboxylate 1 . This final step is catalysed by isoprenylcysteine carboxyl methyltransferase (ICMT), a eukaryotespecific integral membrane enzyme that resides in the endoplasmic reticulum 2 . ICMT is the only cellular enzyme that is known to methylate prenylcysteine substrates; methylation is important for the biological functions of these substrates, such as the membrane localization and subsequent activity of RAS 1 , prelamin A 3 and RAB 4 . Inhibition of ICMT has potential for combating progeria 3 and cancer 5-8 . Here we present an X-ray structure of ICMT, in complex with its cofactor, an ordered lipid molecule and a monobody inhibitor, at 2.3 Å resolution. The active site spans cytosolic and membrane-exposed regions, indicating distinct entry routes for the cytosolic methyl donor, S-adenosyl-l-methionine, and for prenylcysteine substrates, which are associated with the endoplasmic reticulum membrane. The structure suggests how ICMT overcomes the topographical challenge and unfavourable energetics of bringing two reactants that have different cellular localizations together in a membrane environment-a relatively uncharacterized but defining feature of many integral membrane enzymes.
Melinda M. Diver 1,2 †, Leanne Pedi 1 , Akiko Koide 3, 4 , Shohei Koide 3, 5 & Stephen B. Long 1 The maturation of RAS GTPases and approximately 200 other cellular CAAX proteins involves three enzymatic steps: addition of a farnesyl or geranylgeranyl prenyl lipid to the cysteine (C) in the C-terminal CAAX motif, proteolytic cleavage of the AAX residues and methylation of the exposed prenylcysteine residue at its terminal carboxylate 1 . This final step is catalysed by isoprenylcysteine carboxyl methyltransferase (ICMT), a eukaryotespecific integral membrane enzyme that resides in the endoplasmic reticulum 2 . ICMT is the only cellular enzyme that is known to methylate prenylcysteine substrates; methylation is important for the biological functions of these substrates, such as the membrane localization and subsequent activity of RAS 1 , prelamin A 3 and RAB 4 . Inhibition of ICMT has potential for combating progeria 3 and cancer [5] [6] [7] [8] . Here we present an X-ray structure of ICMT, in complex with its cofactor, an ordered lipid molecule and a monobody inhibitor, at 2.3 Å resolution. The active site spans cytosolic and membrane-exposed regions, indicating distinct entry routes for the cytosolic methyl donor, S-adenosyl-l-methionine, and for prenylcysteine substrates, which are associated with the endoplasmic reticulum membrane. The structure suggests how ICMT overcomes the topographical challenge and unfavourable energetics of bringing two reactants that have different cellular localizations together in a membrane environment-a relatively uncharacterized but defining feature of many integral membrane enzymes.
ICMT from the beetle Tribolium castaneum exhibited superior biochemical stability in detergent-containing solutions in comparison to other orthologues and was used for biochemical characterization and structure determination (see Methods). Human and beetle ICMT share the same predicted topology 9 and have 58% amino acid sequence identity within the region thought to contain the active site 10 (amino acids 90-281; Extended Data Fig. 1 ). Beetle ICMT demonstrated robust methylation of prenylcysteine substrates both in cellular membranes and in the purified form, and exhibited kinetic parameters similar to those of human ICMT 11, 12 (Extended Data Fig. 2 ). We engineered a synthetic ICMT-binding protein called a 'monobody' , based on a randomized fibronectin protein domain, for use as a crystallization chaperone 13 . The monobody is an inhibitor of ICMT (IC 50 ≈ 1 μ M), and exhibits specificity for the beetle orthologue (Extended Data Fig. 2g, h) . Crystals of purified ICMT-monobody complex were obtained in the lipidic-cubic phase 14 in the presence of the S-adenosyll-homocysteine (AdoHcy) cofactor and the prenylcysteine substrate N-acetyl-S-geranylgeranyl-l-cysteine (AGGC) (Extended Data Fig. 2a ). Experimental phases yielded high-quality electron-density maps that enabled the placement of all amino acids of ICMT and the monobody (Extended Data Fig. 3a ). The refined atomic coordinates have good stereochemistry and an R free value of 24.6% (Extended Data Table 1 ).
ICMT contains eight transmembrane α -helices (M1-M8) and would reside almost entirely within the endoplasmic reticulum membrane in a cellular context (Fig. 1a, b) . The largest cytosolic region of the enzyme, which protrudes approximately 12 Å away from the membrane and encompasses the binding site for AdoHcy, is formed by an extension of M8 together with a structurally ordered connection between M6 and M7 (the M6-M7 connector) plus a short 'cap' helix near the C terminus. The M6-M7 connector does not fully reach the luminal side, but is stabilized within the transmembrane region by interactions with the M5-M6 connector, which lies beneath it ( Fig. 1b and Extended Data Fig. 4a ). Additionally, the M5 helix would not span the bilayer. Its N terminus, capped by a hydrogen bond with Ser128, is positioned within the membrane region, about 10 Å from the cytosolic side ( Fig. 1 and Extended Data Fig. 5b ). Unusually, the M4 and M5 helices are connected by a 25 Å-long extended segment (Pro115-Pro129) that traverses diagonally in the membrane-spanning region ( Fig. 1c and Extended Data Fig. 5a ). The M1-M3 region, which is unique to ICMT enzymes from animals (Extended Data Fig. 1 ), makes extensive contacts with M4 and the M4-M5 connector. Helices M1, M2 and M3 associate with one another and are stabilized, in part, by GXXXG-like helical packing motifs between M1 and M3 15 (Extended Data Fig. 6a ). The non-covalent association is strong enough that M1 and M2 remain associated with the core of the enzyme following proteo lytic cleavage of the M2-M3 loop (Extended Data Fig. 6 ). Congruently, genetic deletion of M1 and M2 renders human ICMT inactive 12 .
The structure provides context for a large body of functional data on ICMT [9] [10] [11] [12] 16 . Residues that disrupt catalytic activity when mutated define the active site on the structure ( Fig. 2a ), the location of which had remained elusive owing to the broad distribution of these residues in the primary structure (Extended Data Fig. 1 ). In the cell, the active site would be located mostly within the cytosolic leaflet of the membrane, and is contained between M4 and the C terminus in the primary structure ( Fig. 2a ). AdoHcy is encapsulated within a pocket that secludes it from both the aqueous environment of the cytosol and the lipid membrane, and is formed by the M6-M7 connector, the cytosolic extension of M8 and the cap helix ( Fig. 2b, c) . The release of AdoHcy and the subsequent binding of S-adenosyl-l-methionine (AdoMet) could occur via hinged displacement of the M6-M7 connector towards the cytosol, in which there is a reservoir of micromolar concentrations of AdoMet; Gly181 and Ser193 are potential hinge points for this mechanism (Fig. 2c ). The perfectly conserved residues Phe184, Tyr204 and Glu250 appear to be particularly important for positioning AdoHcy through direct contacts (Fig. 2c ), and completely abolish activity when mutated to alanine 12, 16 (Extended Data Fig. 1 ). The active site could accommodate the methyl group of AdoMet in a slender 'tunnel' (Fig. 2b and Extended Data Fig. 4c ), suggesting that the observed conformation of AdoHcy is analogous to the conformation when the methyl donor is bound.
ICMT accommodates a breadth of protein substrates. This includes all prenylated (farnesylated and geranylgeranylated) and proteolytically Letter reSeArCH processed CAAX proteins, as well certain RAB GTPases that have two geranylgeranyl groups attached to the cysteine residues of their C-terminal CXC motif 1 . The structure suggests that the prenyl moiety of the substrate binds in a deep cavity within the active site that extends from the cofactor pocket into the transmembrane region (Figs 2b and 3a). This cavity is approximately 22 Å long and 6 Å wide, and is formed by regions of the M4, M5, M7 and M8 helices. Approximately two thirds of the cavity would be exposed to the cytosolic leaflet of the lipid bilayer via a lateral crevice between helices M5 and M8 (Figs 2b and 3b). A tube of electron density consistent with a lipid is present in the cavity (Fig. 3a) . Although the 20-carbon geranylgeranyl group of the AGGC substrate that was present during crystallization could account for the density, we cannot be sure of its identity, and therefore modelled a monoolein lipid into the density ( Fig. 3a and Extended Data Fig. 3b ). The cavity would also accommodate the 15-carbon farnesyl group. Similar to the binding site for the prenyl group in water-soluble enzymes such as farnesyltransferase 17 , the proposed prenyl-binding cavity is lined primarily by aromatic amino acids (Tyr95, Met99, Phe102, Val124, Asn126, Tyr131, Trp215, Trp218, Tyr235, Phe242 and Phe243) that markedly reduce enzyme activity when mutated 12 (Extended Data Fig. 1 ). For doubly geranylgeranylated CXC proteins, the second prenyl group could be accommodated in the crevice between M5 and M8 and/or in the adjacent membrane while the C-terminal geranylgeranyl group occupies the active site.
The structure of a methyltransferase from the prokaryotic organism Methanosarcina acetivorans, which we refer to as MaMTase, highlights the diversity within the integral membrane methyltransferase family 16 (Extended Data Fig. 7 ). Despite sharing only 14% sequence identity with ICMT, MaMTase was previously referred to as Ma-ICMT, but this nomenclature was misleading because its biological substrates are unknown, it cannot methylate prenylated-peptide substrates 16 and there are no known prenylated proteins in prokaryotes. Nevertheless, the binding sites for AdoHcy are analogous in ICMT and MaMTase (Extended Data Fig. 7 ) and the cofactor-binding domain of ICMT, which spans from M6 through the cap helix, shares a recognizable fold not only with regions of MaMTase, but also with regions of a prokaryotic integral membrane sterol reductase that utilizes a nicotinamide adenine dinucleotide phosphate (NADP + ) cofactor 16, 18 ; this suggests that this domain represents a structural motif for soluble cofactor binding to integral membrane enzymes (Extended Data The monobody inhibitor binds ICMT adjacent to the active site and interacts with portions of M5, M8 and the M6-M7 loop (Fig. 3c ). The 'FG loop' of the monobody, which is diversified in the combinatorial library 13 , dips into the membrane region and presents a tryptophan residue (Trp80) that occupies part of the crevice between M5 and M8 ( Fig. 3d ). It also contacts a portion of the modelled lipid. Although monobodies typically recognize native surfaces of their cognate proteins 19 , to evaluate whether the structure of ICMT was affected Residues that diminish specific activity by more than 95% when mutated 12 (Extended Data Fig. 1 ) are drawn in magenta on a ribbon representation. The high concentration of such residues within the dashed region demarcates the active site. b, The active site, depicted as a molecular surface within the ribbon representation. The AdoHcy pocket is cyan; the membrane-exposed cavity is orange. c, Interactions with AdoHcy (sticks with cyan carbon atoms). Dashed lines indicate hydrogen bonds. Water molecules are shown as red spheres. Nitrogen, blue; oxygen, red; and sulfur, green. The M6-M7 connector is tan. Arrows mark the locations of Gly181 and Ser193; parentheses indicate hydrogen bonds with backbone atoms. Inset shows electron density for AdoHcy (simulated annealing omit F o -F c map, contoured at 3σ).
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by the monobody, we determined a 4.0 Å resolution X-ray structure of ICMT without the monobody (Methods). The only discernable difference is a slight (around 5°) tilting of M5, which could also be due to crystallization in detergent rather than lipidic cubic phase and/or a degree of inherent flexibility ( Fig. 3e and Extended Data Fig. 3e ; the overall r.m.s.d. for Cα atoms is 0.5 Å). The lengthy lipid-binding cavity and the crevice between M5 and M8 leading to it, hallmark features of the active site, are present without the monobody. The location of the monobody suggests that it would prevent prenylated substrates from reaching the active site and/or block product release. Hydrogen bonding between Ser77 of the monobody and Arg246 of ICMT may also contribute to its inhibitory function ( Fig. 3d ), as we predict that Arg246 coordinates the C-terminal carboxylate of the prenylcysteine. Although specific contacts between ICMT and cognate protein substrates are expected to be confined to their prenylcysteine moieties [20] [21] [22] , the positioning of the monobody adjacent to the active site and on the cytosolic side above the crevice between M5 and M8 may demarcate the approximate location of a protein substrate as its C-terminal prenylcysteine undergoes methylation (Figs 3c and 4a). Hydrophobic molecules that bind in the crevice would be expected to inhibit the enzyme; this may be the mode of action of some existing ICMT inhibitors.
The protein substrates of ICMT are amphipathic; their prenyl group or groups partition into the endoplasmic reticulum membrane 1 , and their C-terminal carboxylate and variable protein portions are hydrophilic and exposed to the cytosol. The crevice between M5 and M8, which would be accessible to the hydrophobic core of the membrane and leads directly to the active site, provides a plausible route for prenyl entry by lateral diffusion (Fig. 4a ). The positions of the N-terminal end of M5 and the M4-M5 connector create a hydrophilic depression within the membrane-embedded region of ICMT, and might induce a concomitant depression in the proximal lipids of the bilayer (Extended Data Figs 3c and 9) that would accommodate the upstream peptide, as has been modelled for KRAS4B ( Fig. 4a ). Suggestive of an important role, the M4-M5 connector is highly conserved and greatly diminishes catalytic activity when mutated 12 ( Fig. 2a and Extended Data Fig. 1 ). Hydrophobic residues (Phe123, Val124 and Leu125) presumably anchor it in the membrane, and hydrophilic residues (Asn126, His127 and Ser128) give it amphipathic character (Extended Data Fig. 5a ). The enzyme appears to achieve substrate specificity by the distinct position, shape, proportion and amphiphilicity of its active site.
We constructed a model of a transition state based on the structure of ICMT (Fig. 4b ). The negatively charged carboxylate of the prenylcysteine substrate, the nucleophile in the direct-transfer mechanism, is coordinated and positioned for catalysis by two arginine residues, Arg173 (on M6) and Arg246 (on M8), which also provide specificity for the carboxylate. In the X-ray structure, Arg173 and Arg246 are stabilized by hydrogen-bonding networks and two water molecules occupy the proposed location of the carboxylate (Extended Data Fig. 4b ). Similar to other methyltransferases that use AdoMet as the methyl donor 23 , and supported by mutagenesis data 12 (Extended Data Fig. 1 ), we predict that the methyl group of AdoMet makes three unconventional hydrogen bonds involving carbon as the hydrogen-bond donor that help stabilize the transition state ( Fig. 4b ). 
A recent study indicates that human ICMT has a synthetic lethal interaction with oncogenic RAS 8 , suggesting that ICMT inhibitors could be effective against RAS-driven cancers. ICMT inhibitors may also be useful for treating progeria, the pathology of which is attributed to the accumulation of a prenylated and methylated form of prelamin A at the nuclear envelope 3, 24 . This structure of ICMT will contribute toward efforts to develop inhibitors. More generally, our study describes the atomic structure of an intramembrane enzyme, a class of proteins for which a relatively small number of structures have been determined. Many enzymes that are embedded in biological membranes facilitate the access of reactants that have drastically different physiochemi cal properties to a common active site and maintain them in close proximity for catalysis. The structure provides insight into how one enzyme accomplishes these complex tasks while maintaining specificity for its diverse substrates.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MethODS Cloning, expression, and purification of ICMT. T. castaneum (beetle) ICMT (UniProt accession D6WJ77) was selected as a candidate for protein purification and crystallization trials from among 76 eukaryotic ICMT orthologues that were evaluated using the fluorescence-detection size-exclusion chromatography (FSEC) pre-crystallization screening technique 12, 25 . The cDNA (synthesized by Bio Basic) was ligated into the EcoRI and SalI restriction sites of the Pichia pastoris expression vector pPICZ-C (Invitrogen Life Technologies) and encodes the full-length protein followed by a C-terminal antibody-affinity tag (Ala-Ala-Glu-Gly-Glu-Glu-Phe) that is recognized by the anti-tubulin antibody YL1/2 26 . For the crystals of ICMT alone, two point mutations of surface residues were introduced to improve crystallizability (G151A and E154A). Transformation into P. pastoris, expression and cryo-lysis were performed as previously described 27 .
Lysed cells (40 g) were re-suspended in 200 ml of buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM KCl, 2 mM tri(2-carboxyethyl)phosphine (TCEP, Soltec Ventures; a 275 mM stock solution of TCEP was prepared in 1 M KOH to yield pH ~ 7.5), 2 mM CaCl 2 , 25 μ M AdoHcy, 0.15 mg/ml DNase I (Sigma-Aldrich), 1:1,000 dilution of Protease Inhibitor Cocktail Set III (EDTA free, CalBiochem), 1 mM benzamidine (Sigma-Aldrich), 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF, Gold Biotechnology) and 1:1,000 dilution of aprotinin (Sigma-Aldrich). Cell lysate was adjusted to pH 7.5 using 1 M KOH, 2 g decyl maltose neopentyl glycol (DMNG, Anatrace) was added to the cell lysate and the mixture was stirred at room temperature for 45 min to extract ICMT from the membranes. The sample was then centrifuged at 43,000g for 40 min at 12 °C and the supernatant was filtered through a 0.22-μ m polystyrene membrane (Millipore). YL1/2 antibody (IgG, expressed from hybridoma cells and purified by ion-exchange chromatrography using standard methods) was coupled to CNBr-activated sepharose beads (GE Healthcare) according to the manufacturer's protocol. Approximately 0.4 ml of YL1/2 antibody beads were added to the sample for each 1 g of P. pastoris cells and the mixture was rotated at room temperature for 1 h. Beads were collected on a column, washed with four column volumes of buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM KCl, 2 mM TCEP, 2 mM CaCl 2 , 25 μ M AdoHcy and 1 mM DMNG, and the protein was eluted with buffer containing 100 mM Tris-HCl, pH 7.5, 150 mM KCl, 2 mM TCEP, 2 mM CaCl 2 , 25 μ M AdoHcy, 1 mM DMNG and 5 mM Asp-Phe peptide (Sigma-Aldrich) or Glu-Glu-Phe peptide (Peptide 2.0). ICMT-monobody co-crystallization in lipidic cubic phase. Following elution from the antibody-affinity column, the protein was combined with the monobody (designated MB-15) in a 1:3 molar ratio (ICMT:monobody). The mixture was concentrated to 500 μ l using a 30-kDa concentrator (Amicon Ultra, Millipore) and the ICMT-monobody complex was purified using a Superdex 200 Increase size-exclusion column (GE Healthcare) in 10 mM Tris-HCl, pH 7.5, 150 mM KCl, 5 mM TCEP, 2 mM CaCl 2 , 25 μ M AdoHcy and 0.2 mM DMNG. The fractions corresponding to the ICMT-monobody complex and the free monobody were combined (to ensure an excess of monobody), 500 μ M AdoHcy was added, and the sample was concentrated to ~ 10 mg/ml using a 100-kDa Vivaspin-2 concentrator (Satorius Stedim Biotech). Some of the excess monobody passed through the concentrator. Following concentration, 1 mM N-acetyl-S-geranylgeranyl-lcysteine (AGGC, from a 100 mM stock in DMSO, Enzo Life Sciences) was added before crystallization.
The ICMT-monobody complex was combined with a mixture of 9.9 monoacylglycerol (monoolein, Nu-Chek Prep) at a ratio of 40:60 (v:v, ICMT:monoolein) using a manual syringe mixer at 20 °C following an established protocol 14 . A Gryphon LCP robot (Art Robbins Instruments) was used to dispense 50-nl mesophase drops onto 96-well glass sandwich plates (Marienfeld). The LCP boluses were overlaid with 800 nl precipitant solution. Drops were sealed with a glass coverslip, incubated at 20 °C and imaged periodically using a RockImager (Formulatrix). The precipitant solution for the best crystal consisted of 30% PEG 400, 100 mM NaCl and 100 mM Na HEPES, pH 7.5. Crystals also grew in other salts, including 100 mM LiSO 4 and 100 mM AmSO 4 . Crystals appeared after one day and reached approximately 30-60 μ m in size within two to three days. To collect the LCP crystals, the glass coverslip was scored using a glass cutter, the LCP bolus was overlaid with ~ 2 μ l of additional precipitant solution, and the crystals were collected using MiTeGen MicroMounts and submerged in liquid nitrogen. Crystallization in detergent. ICMT was purified as described above except that 1 mg/ml total brain lipids (Avanti) was added to the purification buffers. The elution from the antibody affinity column was concentrated to 500 μ l using a 50-kDa concentrator (Amicon Ultra, Millipore) and applied to a Superdex 200 Increase size-exclusion column (GE Healthcare) that was equilibrated in 10 mM Tris-HCl, pH 7.5, 150 mM KCl, 5 mM TCEP, 2 mM CaCl 2 , 25 μ M AdoHcy, 1 mM DMNG and 0.02 mg/ml total brain lipids. Fractions containing ICMT were pooled, supplemented with 500 μ M AdoHcy, and concentrated to 5-10 mg/ml using a 50 kDa concentrator (Vivaspin-2; Sartorius). ICMT crystals were obtained by vapour diffusion using 300 nl ICMT and 300 nl crystallization solution and a Mosquito crystallization robot (TTP Labtech) over reservoirs containing 100 μ l precipitant solution. The crystals were obtained from 24-28% PEG400 (v/v), 200 mM CaCl 2 or 200 mM MgCl 2 , 50 mM Na acetate, pH 5.0-6.5, at 4 °C and reached a size of approximately 100-400 μ m within two to three weeks. The crystals were then transferred through a series of five steps using the components of an equilibrated drop to increase the PEG 400 concentration to 35% before flash-cooling in liquid nitrogen. Monobody generation. General methods for phage-and yeast-display library sorting and gene shuffling have been described 13, 28 . His 10 -tagged beetle ICMT protein, purified from P. pastoris and solubilized in 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 25 μ M AdoHcy, 50 μ M AGGC and 1 mM DMNG, was mixed with an equimolar concentration of BTtrisNTA, a high-affinity His-tag ligand conjugated with biotin 29 , so as to capture the target proteins with streptavidin magnetic beads in phage-display selection and to detect them with fluorescent dye-labelled streptavidin in yeast-surface-display experiments 30 . Two separate monobody libraries, denoted 'loop' and 'side' , were used to generate monobodies with diverse binding-surface topography 13 . Four rounds of phage-display library sorting were performed using target concentrations of 100, 100, 100 and 50 nM for the first, second, third and fourth rounds, respectively, at room temperature. Three rounds of yeast display library sorting were performed, using a fluorescence-activated cell sorter (FACSAria, BD Biosciences). The first round was to enrich clones that did not bind to 500 nM BTtrisNTA but without ICMT (negative sorting), and the second and third rounds were to enrich clones that bound to 500 nM and 250 nM ICMT-BTtrisNTA complex (positive sorting). Target binding of individual clones was tested using yeast display and three were selected for purification. The monobody proteins were expressed in Escherichia coli using the expression vector pHBT, which adds an N-terminal His 6 tag followed by a biotin-acceptor tag and a TEV-cleavage site 31 . Co-crystallization with one of these monobodies (designated MB-15) yielded crystals with good diffraction. For purification of MB-15, frozen cells were mechanically lysed in a mixer mill (Retsch model PM 100; 8 × 3 min at 400 r.p.m.) using steel balls. Lysed cells (6 g) were re-suspended in 50 ml buffer containing 50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 0. Purified MB-15 was stored at − 80 °C until use. Structure determination. X-ray data were collected at beamlines 23ID-D and 24ID-C of the Advanced Photon Source (APS, Argonne). Diffraction data were collected using an oscillation angle of 0.3° and high redundancy was obtained by collecting data from multiple locations throughout the crystals. For phasing of the ICMT-monobody complex, Se-Met labelled ICMT protein was generated by producing the enzyme in High Five insect cells (Invitrogen) using a baculovirus system with standard techniques. Diffraction data were processed using the HKL3000 suite 32 . The crystals diffracted X-rays to 2.3 Å resolution and each asymmetric unit contained one ICMT-monobody complex. Initial experimental phases (35-4 Å) for the ICMT-monobody complex (space group P2 1 2 1 2 1 ) were determined using the SIRAS phasing method in SHARP and improved using solvent flattening 33 . Five Se-Met sites were located; they correspond to the five methionine residues of ICMT. Electron density for the monobody was discontinuous in these maps. The monobody was placed in the asymmetric unit using molecular replacement (using an ensemble of monobody structures, PDB ID: 3UYO, 1FNA, 2QBW and 2OCF, and a homology model of MB-15 based on PDB ID: 3UYO) in Phaser 34 . At this point, well-defined electron density was observed for the entire complex. The atomic model was constructed using Coot and improved through iterative cycles of refinement using CNS and PHENIX [35] [36] [37] . Model validation was performed with MolProbity 38 . Each unit cell contains one ICMT-monobody complex. Data collection, phasing, and refinement statistics are shown in Extended Data Table 1 .
The structure of ICMT in the absence of the monobody (space group C222 1 ) was determined by molecular replacement using the refined 2.3 Å resolution structure of ICMT from the monobody complex as a search model in Phaser 34 .
Letter reSeArCH X-ray diffraction from the crystal of ICMT without monobody was anisotropic and the dataset was truncated to 4.2 Å resolution along b* using the Diffraction Anisotropy Server 39 . The electron density maps from Phaser showed continuous electron density throughout the model and indicated slight tilting of M5. The model was adjusted accordingly in Coot and refined in Phenix 36, 37 . A composite simulated-annealing omit-electron density map was constructed using Phenix 36 and this map confirmed that the only discernable difference in the overall structure was the tilting of M5 ( Fig. 3e and Extended Data Fig. 3e ). Molecular graphics figures were prepared using PyMOL (http://www.pymol.org). Enzymatic assay. The catalytic activity of ICMT was measured using a previously described assay, with slight modifications, to monitor [ 3 H]methyl incorporation into biotin-S-farnesyl-l-cysteine (BFC) 11, 12 . For these assays, ICMT was either purified (as described above; using 0.2 mM DMNG detergent) or present as a GFPfusion protein in HEK293-cell lysate 12 (GFP was fused to the N terminus and an AAEGEEF tag was present on the C terminus). For experiments using GFP-tagged ICMT, the preparation of the cell lysate and the determination of the ICMT concentration from the GFP fluorescence were as previously described 12 . The enzyme, either as purified ICMT in DMNG detergent or as GFP-ICMT in HEK293-cell lysate, was diluted into reaction buffer containing 150 mM NaCl, 5 mM MgCl 2 , 1mM DTT and 100 mM HEPES pH 7.4 to yield an ICMT protein concentration of approximately 10 nM. For experiments using purified protein, the reaction buffer was supplemented with 10 μ M DMNG. For the initial velocity curves, the data were fitted using GraphPad Prism 7 software as previously described 12 . For experiments used to study the effect of the monobody on activity (Extended Data Fig. 2f, g) , enzymatic assays were performed with varying concentrations of monobody, a fixed amount (~ 10 nM) of enzyme, 5 μ M BFC and 4 μ M AdoMet, using either purified beetle ICMT or one of the following GFP-tagged ICMT orthologues in HEK293 cell lysate: beetle ICMT, human ICMT or Anopheles gambiae ICMT 12 .
For initial velocity curves, the data were fitted to the following models using least-squares nonlinear regression with GraphPad Prism 7 software: (1) for the initial velocity versus AdoMet concentration curves, a Michaelis-Menten model was used, Y = V max X/(K m + X); (2) for the initial velocity versus BFC concentration curves when substrate inhibition was not observed, an allosteric-sigmoidal model was used, Y = V max X h /(K half h + X h ); and (3) for the initial velocity versus BFC concentration curves when substrate inhibition was observed, an allostericsigmoidal model that takes into account substrate inhibition was used, Y = V max X h / (K half h + X h (1 + X h /K i h )). In these equations Y is the initial velocity, X is the substrate concentration, h is the Hill coefficient, V max is the maximum enzyme velocity, K half and K m are the concentrations of half-maximal velocity for sigmoidal and Michaelis-Menten models, respectively, and K i is the inhibition constant. For experiments where the concentration of BFC was varied, 5 μ M AdoMet was used. For experiments where the concentration of AdoMet was varied, 4 μ M BFC was used. To account for the background activity due to endogenous human ICMT in the HEK293 cell lysate, initial velocity curves were constructed using lysate from cells transfected with GFP alone and subtracted for all analyses. The effective BFC concentration was corrected for the small amount of BFC that binds to plasticware used in the assay as described 12 . FSEC and western analysis of ICMT using a cleavable M2-M3 linker. cDNA encoding beetle ICMT was cloned into the pNGFP-EU expression vector 26 using the EcoRI and SalI restriction sites to create an ICMT construct with a 6× His tag and GFP fused to the N terminus (His-GFP-ICMT). A PreScission protease (PS) cleavage site and several flanking amino acids were inserted into the loop between the M2 and M3 helices (introduced between Asn58 and Glu59 to yield the final sequence Asn58-SGSSGSLEVLFQGPSAGGSAGAAS-Glu59, where the underlined region is the PS site) using standard molecular biology techniques. These constructs, with or without the cleavage site, were expressed by transient transfection in HEK293 cells (~ 1.5 × 10 6 cells using Lipofectamine 2000, Invitrogen). HEK293 cells were obtained from ATCC and were not tested for mycoplasma contamination. The cells were pelleted (500g), 48 h after transfection and re-suspended in 300 μ l of buffer consisting of 50 mM NaH 2 PO 4 , pH 7.5, 190 mM NaCl, 10 mM KCl, 20 mM DTT, 200 μ M AdoHcy, 40 mM dodecyl maltoside (DDM, Anatrace) detergent and 1:500 dilution of Protease Inhibitor Cocktail Set III, EDTA-free (CalBiochem). Samples were rotated for 1 h at 4 °C to allow detergent extraction of ICMT from membranes, and then were centrifuged at 20,800g for 1 h at 4 °C. The supernatants, which contained detergent-solubilized ICMT, were divided into two portions. PreScission protease (2 μ g; made in-house, but available from GE Healthcare) was added to one portion. The samples were incubated for 2 h at 4 °C and analysed by anti-His western blot (Anti-His 6 antibody, Roche Cat. # 04905318001) and by FSEC 26 , using a Superose 6 column (GE Healthcare). The running buffer for FSEC was 20 mM NaH 2 PO 4 , pH 7.5, 190 mM NaCl, 10 mM KCl, 5 mM DTT and 1 mM DDM. Data availability. Atomic coordinates and structure factors have been deposited in the Protein Data Bank (PDB) with accession numbers 5V7P (ICMT-monobody) and 5VG9 (ICMT alone). 

Extended Data Figure 1 | The structure identifies functions for key residues. ICMT is displayed as a progression from primary sequence alignment, to the effects of scanning mutagenesis (bar graphs), to observed secondary structure (α -helices depicted as ribbons), to the assigned role of amino acids. Results from scanning mutagenesis experiments 12 are plotted above the sequence alignment as a bar graph showing the reduction of specific activity in comparison to wild-type ICMT, with 0% representing wild-type activity and 100% reflecting no detectable activity (indicated by a horizontal dashed line). The inset key denotes the colouring of the bar graph according to the functional role of the amino acid inferred from the atomic structure. Labelled brackets above the secondary structure denote the general function of the indicated regions of the primary sequence. In the bar graph: magenta, amino acids that contact AdoHcy; red, amino acids that line the lipid-binding cavity; blue, arginine residues that are proposed to form hydrogen bonds with the carboxylate of the prenylcysteine substrate, and the residues that position them; grey, residues proposed to form hydrogen bonds to the methyl of AdoHcy in the transition state; hydrogen bonds made with backbone atoms are indicated by parentheses surrounding the amino acid label. The mutagenesis data are derived from experiments using A. gambiae ICMT 12 , and are normalized for expression level. Except where noted, the mutations were alanine substitutions. In some cases, leucine substitutions (L) were made (for example, when the wild-type amino acid was a glycine or alanine). The data represent triplicate measurements for each mutation and the mean s.d. is 11%. Gaps in the bar graph indicate amino acid positions that were not analysed by mutagenesis. Based on size-exclusion chromatography that was performed for each of the mutants, only the E141A mutation was found to be notably destabilizing (asterisk). A few mutations increased the activity relative to wild-type; these are shown as exhibiting 0% reduction in activity. The amino acid sequences included in the alignment are: T. castaneum ICMT (beetle ICMT), human (Hs), A. gambiae (Ag), Saccharomyces cerevisiae (Sc), and Arabidopsis thaliana (At) (UniProt accession numbers: D6WJ77, O60725, Q7PXA7, P32584 and Q93W54, respectively). The alignment is coloured according to the ClustalW convention. 
Extended Data Figure 6 | The M1-M2 portion of ICMT is an integral part of the enzyme. a, The GXXXG packing motif between helices M1 and M3 of ICMT. Residues on M1 and M3 that make contacts between these helices are drawn as sticks and coloured magenta. Because the M1 and M2 helices are not present in S. cerevisiae ICMT, we hypothesize that the GXXXG motif in the first transmembrane helix of yeast ICMT (equivalent to M3 of beetle ICMT) may cause dimerization of the yeast enzyme through packing of these helices 40 , whereas ICMT enzymes that contain M1 and M2, which include human and beetle ICMT, are monomeric. The location of a PreScission protease cleavage site (PS site) that was introduced at Asn58, in the connection between the M2 and M3 helices, for experiments outlined in this figure, is indicated. b, Anti-His western blot showing that this cleavage site can be cleaved by PreScission protease. In this experiment, ICMT was expressed in HEK293 cells with an N-terminal His-GFP tag (His-GFP-ICMT), with or without the cleavage site. The addition of PreScission protease to detergent-solubilized sample 4 (His-GFP-ICMT with the cleavage site), but not control samples 1-3, results in a cleavage product consisting of His-GFP followed by amino acids 1-58 of ICMT (His-GFP-ICMT 1-58), which is detected by anti-His western blot. This confirms that the loop connecting the M2 and M3 helices is cut by the protease. Samples 1-3 are control experiments, as indicated. For gel source data, see Supplementary Fig. 1. c The portion that binds AdoHcy is coloured cyan and is partially transparent to reveal a stick representation of the cofactor. The cavity that would be exposed to the membrane and forms the presumed binding site of the prenylcysteine moiety of the substrate is coloured orange. An arrow marks a pathway by which the prenyl group of the substrate could reach the active site via the membrane. Horizontal lines denote the approximate boundaries of the endoplasmic reticulum membrane. b, Overall structure of MaMTase (PDB ID: 4A2N) shown in two orientations, obtained by superposing with ICMT. A cavity, denoting the active site, is drawn as a molecular surface. The portion in which AdoHcy binds is coloured cyan; the remainder is dark grey and is likely to represent the binding site of its biological substrates, which are unknown. Structural elements are coloured as for ICMT in a. The cavity is exposed to the membrane on the opposite side of the enzyme relative to ICMT. Instead of a crevice between the magenta-and dark-blue-coloured helices like ICMT (H2 and H5 of MaMTase, which roughly correspond to M5 and M8 of ICMT, respectively), MaMTase has a crevice between H1 (light blue) and H2 (magenta), suggesting that its substrates access it from the 'right' (arrow) rather than from the 'left' . In ICMT, this route is blocked by the M4-M5 linker. The dimensions of the cavity in MaMTase and its exposure to the membrane suggest that the substrates of MaMTase are hydrophobic molecules that are smaller than a farnesyl or geranylgeranyl prenyl group. c, Overall structure of the prokaryotic integral membrane sterol reductase MaSR1 (PDB ID: 4QUV) 18 . The orientation is based on superposition of the cofactor-binding domain with ICMT, with corresponding colouring. The carbon atoms of a bound NADPH cofactor are coloured cyan. A crevice between the magenta and dark blue-coloured helices may serve as access for lipophilic sterol substrates 18 (arrow). /ε) , where | F| is the heavy-atom structure-factor amplitude and ε is the residual lack of closure error (r.m.s. is root mean square). Rcullis is the mean-residual lack-of-closure error divided by the dispersive or anomalous difference. R-factor = Σ | Fo− Fc| /Σ | Fo| , where Fo and Fc are the observed and calculated structure factors, respectively. Rfree = R-factor calculated using a subset (~ 5%) of reflection data chosen randomly and omitted throughout refinement. Numbers in parentheses indicate the highest-resolution shells and their statistics.
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Data exclusions
Describe any data exclusions. No data were excluded from the analyses.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful. Crystals consistently grew under the indicated conditions and diffracted to similar resolution.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
As is standard practice in X-ray crystallography, a random set of structure factors were held aside during the refinement and were used to calculate R(free), as indicated in the Methods and Extended Data Table 1 .
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were blinded to the randomly selected set of structure factors that were used to calculate R(free).
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance. Describe the software used to analyze the data in this study.
All software used is indicated in the Methods, and consists of published, publicly available, software used routinely for X-ray crystallography. This includes: Phenix, coot, pymol, and CNS.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no restrictions on availability of unique materials.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). The study did not involve human research participants.
Anti
